Hoffmann, Marc Steven

Phase 1b Trial of Cereblon-Modulating Agents Iberdomide and CC-99282 Plus R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9475-9477

10.1182/blood-2022-162774